A cancer diagnosis — even one fully treated years ago — is one of the most complex underwriting scenarios in life insurance. Outcomes range from standard rates for certain early-stage skin cancers to outright decline for recent or metastatic disease. The type of cancer, stage, treatment, and time since last treatment are the four variables that drive everything.
What Underwriters Evaluate for Cancer History
Every cancer case is reviewed individually. These are the factors that determine whether you qualify, at what rating, and with which carrier:
Type of Cancer — Carriers treat cancer types very differently. Basal cell skin cancer is generally ignored. Thyroid cancer (papillary) and early-stage prostate cancer often qualify for standard rates after treatment. Breast, colon, and melanoma require more time and scrutiny. Lung, pancreatic, brain, and esophageal cancers — especially with any recurrence — are the most restrictive categories.
Stage at Diagnosis — Stage 0 (carcinoma in situ) and Stage 1 are treated most favorably; many qualify for standard or mildly rated offers after an appropriate waiting period. Stage 2 and 3 require longer waiting periods and typically result in table ratings. Stage 4 (metastatic) is a decline at virtually all fully underwritten carriers regardless of treatment outcome.
Time Since Last Treatment — The single most impactful timeline factor. Most carriers require a minimum of 2–5 years in complete remission before offering coverage. For higher-risk cancers, 5–10 years may be required for standard rates. Recent treatment — within the past 12–24 months — results in postponement at most fully underwritten carriers.
Treatment Received — Surgery only is viewed most favorably for localized cancers. Chemotherapy or radiation signals more aggressive disease and typically extends the waiting period. Bone marrow transplant or immunotherapy cases are reviewed individually and often result in decline or very high ratings in the years immediately following treatment.
Recurrence History — Any cancer recurrence significantly worsens the underwriting outcome. A single localized cancer treated successfully is viewed very differently from a cancer that recurred even once. Multiple recurrences typically result in decline or postponement at all standard carriers.
Current Surveillance Status — Active monitoring (regular scans, bloodwork, oncology follow-up) is viewed positively — it demonstrates compliance and ongoing management. Carriers want to see clean surveillance results, not gaps in follow-up care.
Cancer Types: General Underwriting Outlook
Below is a general guide to how carriers approach the most common cancer types. Waiting periods are from date of last treatment with no recurrence. Individual cases vary significantly.
| Cancer Type | Typical Waiting Period | Best Achievable Rating | Notes |
|---|---|---|---|
| Basal Cell Skin Cancer | None required | Standard / Preferred | Generally disregarded by underwriters; treated as non-event |
| Squamous Cell Skin Cancer | 1–2 years (localized) | Standard | Localized and excised; more caution if lymph node involvement |
| Thyroid Cancer (Papillary) | 1–2 years post-treatment | Standard possible | Excellent prognosis; most carriers treat favorably after short waiting period |
| Prostate Cancer (Gleason 6, Stage 1–2) | 1–3 years post-treatment | Standard to Table 2 | Low-grade localized prostate treated favorably; higher Gleason scores require more time |
| Breast Cancer (Stage 1–2, ER+) | 2–5 years post-treatment | Table 2–4 at 2 years; standard possible at 5+ years | Hormone receptor status, lymph node involvement, and treatment type all factor in |
| Colon Cancer (Stage 1–2) | 2–5 years post-treatment | Table 2–4; standard possible at 5+ years | Stage 3 requires 5+ years; regular colonoscopy surveillance viewed positively |
| Melanoma (Clark Level I–II / Stage 1) | 1–3 years (thin lesion) | Standard to Table 2 | Breslow thickness and Clark level are key; deeper invasion requires longer waiting and higher ratings |
| Melanoma (Stage 2–3) | 5–10 years post-treatment | Table 4–8 at 5 years; standard possible at 10+ years | Lymph node involvement significantly increases scrutiny |
| Cervical Cancer (Stage 1) | 2–3 years post-treatment | Standard to Table 2 | CIS (Stage 0) often ignored; Stage 1 treated favorably after waiting period |
| Bladder Cancer (Low-Grade, Non-Invasive) | 2–3 years post-treatment | Table 2–4 | High recurrence rate noted by underwriters; surveillance history matters |
| Hodgkin’s Lymphoma (Stage 1–2) | 5 years post-treatment | Table 2–4 at 5 years; standard possible at 10+ years | Good long-term prognosis; late treatment effects (cardiac, secondary malignancy) monitored |
| Lung Cancer | 5+ years (Stage 1 only) | Table 4–8 minimum; decline at most carriers | Extremely restrictive; Stage 2+ is decline at virtually all carriers regardless of time elapsed |
| Pancreatic Cancer | Postponement / Decline | Decline at virtually all standard carriers | Even with surgery and remission, extremely few carriers will consider; guaranteed issue may be only option |
Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.
Carrier Guidelines: Cancer Underwriting Comparison
Carriers vary significantly in their willingness to cover cancer survivors and in how many years of remission they require. Below are current general approaches across major carriers we represent.
| Carrier | Minimum Remission (Breast/Colon) | Skin Cancer Approach | Notes |
|---|---|---|---|
| Protective Life | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after 1–2 years | Competitive for early-stage breast and colon; strong thyroid and prostate outcomes |
| Banner Life / Legal & General | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed individually | Competitive term pricing for cancer survivors with clean remission records |
| Prudential | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after treatment | Medical director review available for complex cases; competitive for melanoma survivors |
| Pacific Life | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard post-treatment | Strong for prostate cancer survivors; favorable thyroid cancer treatment |
| Transamerica | 2–3 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed case-by-case | More conservative on breast cancer; competitive on pricing at table ratings for qualifying cases |
| North American Company | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after excision | Solid option for straightforward cancer survivor cases; less competitive on complex histories |
| Lincoln Financial | 2 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell standard after treatment | Requires complete oncology records; competitive for well-documented remission cases |
| Mutual of Omaha | 2–3 years (Stage 1); 5 years (Stage 2–3) | Basal cell ignored; squamous cell reviewed individually | Strong simplified issue and final expense options for cases that don’t qualify fully underwritten |
Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.
Situations That Typically Result in Decline
The following scenarios result in postponement or decline at most or all fully underwritten carriers. Alternative products such as graded benefit or guaranteed issue may be available.
Active or Metastatic Cancer (Stage 4) — Any active cancer or Stage 4 diagnosis is a decline at all fully underwritten carriers regardless of treatment response. Graded benefit or guaranteed issue products are available during this period.
Treatment Within the Past 12–24 Months (Most Cancers) — Recent chemotherapy, radiation, or surgery for most cancers triggers a postponement period. Some carriers will consider sooner for very low-risk types, but most require 1–2 years minimum from end of treatment.
High-Mortality Cancers (Lung, Pancreatic, Brain, Esophageal) — Even with treatment and apparent remission, these cancer types are declined or highly restricted at most carriers due to poor long-term survival statistics. Very limited options exist beyond guaranteed issue.
Any Cancer Recurrence — A single recurrence, regardless of cancer type or subsequent remission, significantly restricts your options and may result in decline at most standard carriers for an extended period.
What You Can Do to Improve Your Outcome
Maintain complete oncology records. Pathology reports, staging documentation, treatment summaries, and surveillance scan results are essential. Carriers need the complete picture — gaps in records raise more concern than the cancer history itself.
Keep up with surveillance appointments. Regular oncology follow-up and clean surveillance results demonstrate ongoing remission and reduce perceived risk. Missing appointments works against you in underwriting.
Time your application strategically. If you’re approaching a key remission milestone (2-year or 5-year), it may be worth waiting. Applying just before that threshold wastes time and creates a declined application in your MIB record.
Work with a specialist broker. Cancer underwriting is among the most carrier-dependent in the industry. The same applicant may be Table 4 at one carrier and standard at another. A specialist who knows current cancer underwriting guidelines across all carriers is essential.
Cancer History? Let’s Find the Right Carrier.
Cancer underwriting requires matching your specific diagnosis, stage, treatment, and time in remission to the carrier whose guidelines are most favorable for your profile. We know which carriers are most competitive for which cancer types — and we’ll tell you before you apply anywhere.